Nippon Shinyaku
As of the edition of 20 October 2026, Nippon Shinyaku runs 14 drugs, 12 of them marketed; it is on route A at 0 targets and on route B at 16 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 1 |
| Status not established | 1 |
| Total | 14 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Cytarabine | none listed | 0 |
| Azacitidine | Ends 2029 (exclusivity) | 4 |
| Tramadol | none listed | 3 |
| Acamprosate | none listed | 10 |
| Ferric derisomaltose | Ends 2029 (patent) | 2 |
| Selexipag | Ends 2030 (patent) | 1 |
| Tagraxofusp | Ends 2030 (computed from the first US licence) | 4 |
| Defibrotide | none listed | 11 |
| Viltolarsen | Ends 2034 (patent) | 0 |
| Defibrotide sodium | none listed | 1 |
| Dexamethasone acefurate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 16 targets.
All 16 rows on route A or B
In the product16 company-target rows on route A or B; 13 are not shown here, and no score is.
See all 16 targets where Nippon Shinyaku needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 1 trials led
- Inherited and neonatal: 1 trials led
- Nervous system: 1 trials led